RxDoctor Payments DataLook up a doctor →

Shelly Shand, MD

Hematology & Oncology · Charleston, SCNPI 1558507848

Payments from drug & device makers

$18,905in general payments, 2019–2025

Across 909 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • AstraZeneca$1K
  • Bristol Myers Squibb$868
  • Johnson & Johnson$834
  • plus $12K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck62$1,442
E.r. Squibb & Sons, L.L.C.72$1,178
Novartis60$1,158
AstraZeneca(2 entities)55$1,010
Bristol Myers Squibb39$868
Johnson & Johnson(2 entities)40$834
Pfizer40$701
Sanofi25$596
Incyte Corporation25$583
Amgen27$578
Gilead(2 entities)22$515
Eisai Inc.25$483
Takeda Pharmaceuticals U.S.A., Inc.20$479
Lilly USA, LLC21$460
Genentech USA, Inc.27$457
Regeneron Healthcare Solutions, Inc.23$437
Seagen Inc.17$434
AbbVie14$376
Puma Biotechnology, Inc.19$347
GSK18$342
Jazz Pharmaceuticals Inc.17$328
Ipsen Biopharmaceuticals, Inc11$326
Daiichi Sankyo Inc.13$316
Rigel Pharmaceuticals, Inc.11$309
Astellas Pharma US Inc8$246
Kyowa Kirin, Inc.5$233
Bayer13$229
Taiho Oncology, Inc.11$228
Secura Bio, Inc.5$202
Beigene USA, Inc.10$195
Karyopharm Therapeutics Inc.8$156
Acrotech Biopharma Inc.6$147
Stemline Therapeutics Inc.5$134
ADC Therapeutics America, Inc.7$133
Dova Pharmaceuticals8$133
Servier Pharmaceuticals LLC6$123
Alnylam Pharmaceuticals Inc.5$121
Beone Medicines USA, Inc.5$110
EMD Serono, Inc.7$107
Tersera Therapeutics LLC4$102
Pharmaessentia USA Corporation4$91
Boehringer Ingelheim3$87
Mirati Therapeutics, Inc.4$83
Exelixis Inc.5$83
Morphosys, US Inc.5$80
Tesaro, Inc.3$70
Pharmacosmos Therapeutics Inc.3$68
Teva Pharmaceuticals USA, Inc.5$67
Sobi, Inc3$60
Fennec Pharmaceuticals, Inc.2$49
Epizyme, Inc.3$47
Adaptive Biotechnologies Corporation2$47
Array Biopharma Inc3$46
Pharmacyclics LLC, An Abbvie Company3$44
Sumitomo Pharma America, Inc.2$43
G1 Therapeutics, Inc.2$42
Shield Therapeutics Inc2$42
Recordati_rare_diseases_inc.2$41
AVEO Pharmaceuticals, Inc.2$40
Apellis Pharmaceuticals, Inc.2$39

How this compares

$18,905 in reported general payments places this provider in the 65th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$120,622
Medicare patients
351
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →